GASTROENTEROLOGY · ROME IV REVIEW · TOPIC: IRRITABLE BOWEL SYNDROME · REF: ACG / Rome Foundation / FDA
The Enteric Atlas Gut-brain reference · U.S. edition
Neurogastroenterology · Functional disorder

IBS is not "all in your head." It is a disorder of the gut-brain axis — and the gut is very real.

Roughly 10 to 15 percent of American adults live with irritable bowel syndrome, and less than half have ever received a diagnosis. The gut looks normal on standard tests, but its nerves are sensitized, its motility is dysregulated, and its microbiome is altered. What follows is the practical map: how it is diagnosed, what the four subtypes mean, and which treatments actually work.

14 min read
Rome IV-aligned
4 subtypes · 4 drug classes
10–15%
Of U.S. adults meet criteria for IBS — about 1 in 7, and most remain undiagnosed.
2:1
Female-to-male ratio in clinical samples. The reason is not fully understood.
~50%
Develop symptoms after an acute GI infection — post-infectious IBS is common.
75%
Report improvement on a properly structured low-FODMAP diet.
Section 01 · The mechanism

Why the gut looks normal on tests — and still hurts.

IBS is not inflammation. It is not autoimmunity, allergy, or cancer. It is a disorder of how the gut and the brain communicate with each other. On endoscopy, in biopsies, and on imaging, the gut appears normal. But the signaling that governs motility, sensation, secretion, and pain perception is dysregulated — and this dysregulation is real, measurable, and treatable.

Four mechanisms work in combination, and the mix differs from person to person. Visceral hypersensitivity — the gut's nerves fire more readily than they should, so normal gas and normal contractions are perceived as pain. Altered motility — the colon moves too quickly (diarrhea-predominant) or too slowly (constipation-predominant), or uncoordinated. Microbiome shifts — the composition of gut bacteria differs from controls, and small intestinal bacterial overgrowth (SIBO) is more common. Immune activation of the mucosa — a low-grade inflammatory signal that does not reach the threshold of visible inflammation but still sensitizes the enteric nervous system.

Layered over all of this is the brain-gut axis — a two-way communication channel running primarily along the vagus nerve. Psychological stress increases visceral sensitivity. Chronic gut symptoms increase anxiety and depression. This is not a patient "making it up." It is a biological loop, and it is the reason treatments that target the brain (neuromodulators, cognitive behavioral therapy, gut-directed hypnotherapy) work as well as treatments that target the gut.

Post-infectious IBS deserves a special note. Roughly one in ten people who experience an acute bacterial gastroenteritis will develop IBS symptoms within 6 to 12 months — and this is one of the strongest pieces of evidence that IBS is not psychological in origin. It is a real, persistent change in gut physiology triggered by a real infectious event.

Section 02 · The criteria

Rome IV — three features, one clinical diagnosis.

IBS is a clinical diagnosis. Extensive testing is not required when the pattern fits and there are no alarm features. The Rome IV criteria exist to make the diagnosis consistent and reproducible.

Rome IV criteria · recurrent abdominal pain
At least 1 day/week for the last 3 months · onset ≥ 6 months ago

Related to defecation

Pain improves, worsens, or changes with bowel movements.

+

Change in stool frequency

More or fewer bowel movements than before symptom onset.

+

Change in stool form

Consistency shifts toward looser or harder, described on the Bristol scale.

Two of three features must be present, alongside the pain itself. The diagnosis requires the pattern, not the severity — mild and severe IBS both meet the same criteria. A basic workup rules out the common mimics: complete blood count, celiac serology, C-reactive protein, and in some cases fecal calprotectin or thyroid function. Colonoscopy is reserved for patients with alarm features or who are due for colorectal cancer screening.
Section 03 · Four subtypes

IBS-C, IBS-D, IBS-M, IBS-U — the subtype drives the treatment.

IBS is classified by the predominant stool pattern, using the Bristol scale. A subtype can shift over time in the same person, and treatment is adjusted accordingly.

IBS-C
Constipation-predominant

Hard or lumpy stools ≥ 25% of the time

Bristol types 1–2 dominate. Treatment focuses on fiber (soluble, not insoluble), osmotic laxatives, and secretagogues (linaclotide, lubiprostone, plecanatide, tenapanor). Antispasmodics for pain.

IBS-D
Diarrhea-predominant

Loose or watery stools ≥ 25% of the time

Bristol types 6–7 dominate. Treatment includes loperamide, rifaximin, 5-HT3 antagonists (alosetron, ondansetron), and bile-acid binders. Low-FODMAP diet has strong evidence here.

IBS-M
Mixed pattern

Both hard and loose stools ≥ 25% each

Alternating constipation and diarrhea. Treatment often combines antispasmodics, soluble fiber, and neuromodulators (TCAs or SSRIs). Response to single-target medications is often partial.

IBS-U
Unclassified

Meets IBS criteria, no dominant pattern

Stool consistency does not fit C, D, or M. Treatment is symptom-directed and evolves as the pattern clarifies. Some patients eventually shift into a more defined subtype.

Section 04 · The Bristol scale

Seven stool types — the single most useful clinical description.

The Bristol Stool Form Scale is used worldwide to describe stool consistency objectively. In IBS, it determines the subtype and guides the choice of medication.

Bristol Stool Form Scale · types 1–7
Used in IBS classification and monitoring
Type 1Severe constipation

Separate hard lumps, like nuts. Difficult to pass.

Type 2Mild constipation

Sausage-shaped but lumpy. Formed but hard.

Type 3Normal

Sausage-shaped with surface cracks. Ideal.

Type 4Normal

Smooth, soft, sausage-shaped. Ideal.

Type 5Mild diarrhea

Soft blobs with clear-cut edges. Passed easily.

Type 6Moderate diarrhea

Fluffy pieces with ragged edges, mushy.

Type 7Severe diarrhea

Watery, no solid pieces. Entirely liquid.

In IBS, the subtype is determined by which Bristol types occur at least 25% of the time. IBS-C if types 1–2 dominate. IBS-D if types 6–7 dominate. IBS-M if both patterns are above 25%. This matters because medications for IBS-C (secretagogues, osmotic laxatives) can cause diarrhea in IBS-D, and medications for IBS-D (antidiarrheals, bile-acid binders) can cause severe constipation in IBS-C.
Section 05 · The low-FODMAP diet

A three-phase intervention — not an elimination diet for life.

FODMAPs are short-chain carbohydrates that ferment in the colon and draw water into the intestine. In sensitive guts, this triggers bloating, pain, and altered motility. The low-FODMAP diet reduces these specific carbohydrates — then reintroduces them systematically to find personal triggers.

FODMAP traffic lights · common foods
Illustrative · individual tolerance varies
Low FODMAP · generally tolerated

Green — safe to eat during elimination

  • Rice, oats, quinoa, corn
  • Bananas (firm), berries, oranges, kiwi
  • Carrots, zucchini, spinach, potatoes
  • Lactose-free dairy, hard cheeses
  • Chicken, fish, eggs, tofu (firm)
  • Maple syrup, most herbs
Moderate FODMAP · test individually

Yellow — reintroduce in small amounts

  • Broccoli (small portions), sweet potato
  • Avocado (¼), cherries (small)
  • Almonds (10), pumpkin seeds
  • Oat milk, some yogurts
  • Certain sweeteners (sorbitol, mannitol)
High FODMAP · common triggers

Red — typical culprits in IBS

  • Wheat, rye, barley (fructans)
  • Onions, garlic (fructans)
  • Apples, pears, mangoes (fructose)
  • Milk, soft cheeses, ice cream (lactose)
  • Beans, lentils, chickpeas (GOS)
  • Sugar alcohols (sorbitol, xylitol)
Three phases, not one. Phase 1 — strict elimination for 2 to 6 weeks. Phase 2 — systematic reintroduction of one FODMAP group at a time to identify personal triggers. Phase 3 — long-term personalization where the diet is liberalized to the widest range the gut tolerates. Staying on strict elimination indefinitely is not the goal — it narrows the microbiome, may worsen food-related anxiety, and risks nutritional gaps. Working with a registered dietitian substantially improves outcomes.
Section 06 · Medication classes

Four groups of drugs — matched to the predominant symptom.

There is no single IBS drug. Treatment is targeted to the dominant symptom: pain, constipation, diarrhea, or the brain-gut axis itself.

Antispasmodics — for pain and cramping
Taken before meals or as needed

Relax the smooth muscle of the gut wall, reducing spasm-related pain. Best used before meals or in anticipation of a trigger. Meta-analyses show modest but consistent benefit for abdominal pain in IBS.

Peppermint oil is a natural antispasmodic with reasonable evidence, delivered as enteric-coated capsules to release in the intestine rather than the stomach. Dicyclomine and hyoscyamine are the classic prescription antispasmodics — anticholinergic side effects (dry mouth, constipation) are common.

Examplespeppermint oil capsules · dicyclomine · hyoscyamine · otilonium (not in U.S.)
Neuromodulators — for the gut-brain axis
Low-dose · target visceral sensitivity

Low-dose tricyclic antidepressants (TCAs) and SSRIs reduce visceral sensitivity — they act on the enteric nervous system's signaling rather than on mood. The doses are typically lower than those used for depression, and the effect often appears within 2 to 4 weeks.

TCAs (amitriptyline, desipramine) are often preferred for IBS-D because they slow gut transit and reduce diarrhea. SSRIs (paroxetine, citalopram) may be preferred for IBS-C, though evidence is weaker. Common side effects at low doses: drowsiness (TCAs, usually taken at night) or mild nausea (SSRIs).

Examplesamitriptyline · desipramine · paroxetine · citalopram · (gut-directed hypnotherapy and CBT — non-pharmacologic)
Secretagogues — for IBS-C
Increase intestinal fluid secretion

These medications draw water into the intestine, softening stool and accelerating transit. They also reduce visceral pain through a separate mechanism. Approved specifically for IBS-C, and generally well tolerated.

Linaclotide and plecanatide are guanylate cyclase-C agonists given once daily. Lubiprostone is a chloride channel activator. Tenapanor inhibits sodium-hydrogen exchange. The main side effect is diarrhea, which is usually mild but occasionally requires dose reduction. All are brand-only and often expensive without insurance.

Exampleslinaclotide (Linzess) · plecanatide (Trulance) · lubiprostone (Amitiza) · tenapanor (Ibsrela)
Rifaximin — gut-selective antibiotic
For IBS-D · 14-day course

A non-absorbed antibiotic that acts on the gut microbiome without systemic exposure. Approved for IBS-D without constipation. Taken as a 14-day course of 550 mg three times daily, and it can be repeated if symptoms recur.

About 40 percent of patients experience meaningful improvement. Response may relate to underlying small intestinal bacterial overgrowth (SIBO). Probiotics — particularly certain Bifidobacterium and Lactobacillus strains — have modest but mixed evidence; a 4- to 12-week trial is reasonable if a specific strain is used.

Examplesrifaximin (Xifaxan) · specific probiotic strains · (fecal microbiota transplant — investigational in IBS)

Dietary and behavioral interventions are first-line alongside medication. Soluble fiber (psyllium, not wheat bran) helps both IBS-C and IBS-D. Regular physical activity reduces symptom severity. Gut-directed hypnotherapy and cognitive behavioral therapy have strong evidence — comparable to medication in head-to-head trials for IBS — and are increasingly available via telehealth. Sleep quality and stress management measurably affect symptom burden.

What does not work: routine testing for food allergies (IgE tests do not identify IBS triggers), colon cleanses, and long-term elimination diets without reintroduction. Antibiotics are not for all IBS — they are for IBS-D, and repeated courses without clear benefit are discouraged.

Section 07 · What to watch for

Features that mean it is not IBS — or not only IBS.

Rule out organic disease

If any of these appear, further evaluation is required before assuming IBS.

Rectal bleeding or blood in the stool. Not typical of IBS. Requires evaluation — could indicate hemorrhoids, IBD, or colorectal cancer.
Unexplained weight loss, iron deficiency anemia, or fever. Any of these suggests an inflammatory, malignant, or infectious cause. IBS alone does not produce them.
Onset after age 50. New IBS symptoms in an older adult warrant evaluation for organic causes, including colorectal cancer.
Family history of colorectal cancer, IBD, or celiac disease. Increases pre-test probability of an organic condition and changes the diagnostic approach.
Nocturnal symptoms that wake you from sleep. IBS symptoms typically do not wake patients from sleep — diarrhea at 3 a.m. is more characteristic of an inflammatory or infectious process.
Significant change in long-standing IBS symptoms. A stable pattern that suddenly worsens in character or location should prompt reassessment, especially with new alarm features.
Section 08 · Access & affordability

Some IBS medication is generic. Some is not.

The cost landscape in IBS is uneven. Generic options include dicyclomine, hyoscyamine, amitriptyline, desipramine, and most SSRIs, as well as polyethylene glycol (Miralax) for constipation. Peppermint oil capsules and psyllium are over the counter and inexpensive. Brand-only agents include linaclotide, plecanatide, lubiprostone, tenapanor, and rifaximin — all several hundred dollars per month without insurance. Most insurance plans cover them with prior authorization after generic options have been tried.

What still varies at the pharmacy counter: the same generic tablet can cost several times more at one licensed pharmacy than another. For chronic medications like amitriptyline or dicyclomine, even small per-fill differences compound over a year. A live prescription price comparison shows the current range in about two minutes, and the same logic applies to every generic on a patient's list. If you are filling an online refill for the first time, the process is documented step by step in this how to order prescriptions online guide — prescription first, licensed seller second, small first order third.

One practical note: do not stop neuromodulators (TCAs, SSRIs) abruptly. Even at low doses used for IBS, discontinuation symptoms are possible. Tapering should be supervised, even if the dose seems small.

Before filling from any seller — online or local — verify them. A working VIPPS seal that resolves to a live NABP record, a real U.S. street address, and a prescription requirement that cannot be waived. A transparency page like this one about Metformin4You is a reasonable example of the standard to expect.

Section 09 · Questions

Five asked most often at the GI clinic.

Q·01 What is irritable bowel syndrome? +
IBS is a chronic functional disorder of the gut-brain axis characterized by recurrent abdominal pain related to defecation, associated with changes in stool frequency or form. It is not caused by structural damage, inflammation, or cancer — the gut looks normal on standard tests, but its signaling and motility are dysregulated. It affects roughly 10 to 15 percent of adults in the United States.
Q·02 How is IBS diagnosed? +
IBS is diagnosed clinically using the Rome IV criteria: recurrent abdominal pain at least one day per week in the last three months, associated with two or more of the following — related to defecation, associated with a change in stool frequency, or associated with a change in stool form. In the absence of alarm features, extensive testing is usually not required; a basic workup (CBC, celiac serology, CRP, and in some cases fecal calprotectin) rules out the common mimics.
Q·03 Does the low-FODMAP diet work? +
Yes, for many people. Randomized trials show that about 50 to 75 percent of patients with IBS experience meaningful symptom improvement on a low-FODMAP diet. It should be done in three phases — strict elimination for 2 to 6 weeks, systematic reintroduction to identify triggers, and long-term personalization — ideally with a registered dietitian, because the diet is restrictive and not intended for indefinite use.
Q·04 Are probiotics helpful for IBS? +
The evidence is mixed and strain-specific. Some probiotic strains, particularly certain Bifidobacterium and Lactobacillus combinations, show modest benefit in randomized trials. Others show no benefit. Because the effect depends on the specific strain and product, a trial of 4 to 12 weeks with a defined outcome is reasonable, but do not continue indefinitely if there is no benefit.
Q·05 When should I see a doctor about bowel symptoms? +
See a clinician for rectal bleeding, unexplained weight loss, iron deficiency anemia, onset after age 50, a family history of colorectal cancer, inflammatory bowel disease, or celiac disease, fever, nighttime symptoms that wake you from sleep, or a significant change in long-standing symptoms. These features are not typical of IBS and require evaluation.
◆ Sources & Verification
This reference is aligned with public clinical guidance from the American College of Gastroenterology (ACG) IBS Monograph, the Rome Foundation — Rome IV Diagnostic Criteria, the National Institute of Diabetes and Digestive and Kidney Diseases (NIH), and the U.S. Food and Drug Administration's BeSafeRx program. Drug-label information draws on the National Library of Medicine's DailyMed database and MedlinePlus. Pharmacy verification follows the NABP VIPPS program.
◆ Before the next refill

IBS is manageable. The medication should be affordable.

Many IBS medications are available as low-cost generics, and the same tablet can cost several times more at one licensed pharmacy than another. A two-minute comparison across licensed U.S. sellers is a useful habit to build. Begin with the current Metformin price comparison as a live demonstration of how wide the spread runs.

Open the price comparison